Launching the first global, system-level guidance for driving patient access to comprehensive genomic profiling (CGP)

Today, our Advisory team announces the launch of The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to Comprehensive Genomic Profiling (CGP) – the first global, tumor- and country-agnostic roadmap to help health systems embed CGP into routine cancer care at scale.

CGP captures the full spectrum of clinically relevant genomic biomarkers, enabling access to approved targeted therapies and precision medicine clinical trials across a growing number of cancer types. Yet testing remains fragmented, inconsistent, and inequitable. This has created a gap which means only a fraction of patients benefits from a precision medicine approach to treating their cancer.

The newly launched interactive guide provides health ministries, payers, providers, cancer centres, and healthcare consortia with personalized, practical, step-by-step strategic and operational actions to design, implement, scale, and sustain CGP programs within their own system realities. Through uptake of the framework, organizations could make important progress in ensuring precision oncology treatment becomes a tangible reality for patients globally.

Developed through consultation with stakeholders across the genomic testing ecosystem, Avalere Health’s market access specialists identified nine interconnected barriers that continue to restrict access to CGP worldwide. These include strategic, financing, testing infrastructure, test selection, data infrastructure, accreditation, turnaround time, workforce, and education challenges. The resulting guidance, including adaptable frameworks, practical tools, and real-world examples, allows organizations to tailor CGP pathways to their specific healthcare, economic, and regulatory contexts.

“This is the first global framework that recognizes the diversity of health system environments, while offering concrete operational steps to embed CGP into routine practice,” says Amar Urhekar, CEO. “It’s a fantastic example of collaboration between our Advisory and technology experts. They have united to make sense of an extremely complex environment, creating a clear, customizable roadmap that will enable organizations to advance access to precision medicine for every patient possible.”

“As biomarker-driven therapies expand rapidly across tumour types, the ability of health systems to deliver comprehensive genomic profiling is fast becoming a prerequisite for modern cancer care, says Clare Jones, PhD, Executive Director, Global Market Access, Advisory. “The guide aims to accelerate the transition from fragmented testing pathways to integrated precision oncology ecosystems – ensuring innovative therapies can reach every patient possible, faster and more equitably.”

The Pathway to Precision Cancer Care: A Strategic and Operational Guide to Enhance Patient Access to Comprehensive Genomic Profiling (CGP) was funded by the Precision Cancer Consortium. It is now available to healthcare leaders, policymakers, and institutions worldwide. Access the guide here.